Micardis Promotion Cited By FDA For Superiority Claims Over Norvasc, Diovan
This article was originally published in The Pink Sheet Daily
Executive Summary
References included in a Boehringer Ingelheim sales aid for Micardis do not provide sufficient evidence or clinical experience to support the superiority claims, an FDA ad division "untitled" letter states. The agency also cites the sales aid for including unsubstantiated efficacy claims and omitting risk information.